Primary Care in Telford & Wrekin: Demand, Access and the Local Market

Primary care in Telford & Wrekin serves a growing, predominantly urban population with marked differences in health outcomes between neighbourhoods. For a healthcare business, the relevant question is not whether the borough needs more healthcare. It does. The question is which specific service, catchment and purchasing route could support another provider without duplicating existing NHS capacity.

The most recent statutory pharmaceutical evidence is unusually clear. The Telford & Wrekin Pharmaceutical Needs Assessment (PNA) 2026/27–2028/29, approved in March 2026, records 35 community pharmacies, one dispensing GP practice and one dispensing appliance contractor. It concludes that necessary pharmaceutical services are adequately provided, with no current or forecast gap requiring a new NHS pharmacy within the PNA period.

35

Community pharmacies

1

Dispensing GP practice

1

Dispensing appliance contractor

At the same time, the assessment identifies important differences in access, service take-up and health inequalities. It recommends more effective use of pharmacies for hypertension, Pharmacy First, contraception, vaccination, smoking cessation and harm reduction, including in particular localities. That is the difference between provider sufficiency and unmet public-health objectives.

The borough is within NHS Shropshire, Telford and Wrekin Integrated Care Board (ICB), but must not be confused with the larger Shropshire Council area. Its GP network and pharmacy geography are also distinct.

A rapidly growing population with unequal health outcomes

The 2026 PNA records a population of 195,952 in 2024, up 14.9% over the preceding decade. It forecasts 203,230 residents by 2029, with nearly one in five aged 65 or over, and around 4,000 new homes anticipated during its three-year period. Much of this housing growth is expected in the north and central parts of the borough.

This will generate more demand for prescriptions, GP registrations, maternity care, child-health services, chronic-disease management and care of frailty. But the impact varies by neighbourhood and age.

The PNA's four planning localities are Central North, Central South, North East and West. Central South has a younger population and the highest concentration of deprivation. The North East and West have relatively older populations. A clinic for long-term conditions or frailty would therefore evaluate a different catchment from a service for young families or women's health.

The health inequalities are material. The PNA reports that 13% of lower-layer census areas are in England's most deprived 10%, with higher levels in Central South. Life expectancy and healthy life expectancy remain below England averages, and preventable early deaths are a significant concern.

Those needs create an argument for better access and prevention. They do not establish that residents in the most deprived communities can afford expensive private services.

Local GP networks and neighbourhood healthcare

The NHS Primary Care Network (PCN) directory, updated on 29 June 2026, lists nine networks across Shropshire, Telford and Wrekin as a whole.

Four principally relate to Telford & Wrekin:

• Newport/Central PCN, including Donnington Medical Practice, Shawbirch Medical Centre, Linden Hall Surgery and Wellington Road Surgery.
• Teldoc PCN, including Teldoc and Shifnal and Priorslee Medical Practice, whose practice geography intersects the local-authority boundary.
• Wrekin PCN, including Hollinswood, Wellington, Dawley and Charlton.
• South East Telford PCN, including Court Street, Stirchley and Woodside.

The other five networks primarily serve Shropshire Council. A system-wide GP or workforce figure should therefore not automatically be presented as a borough-only statistic.

PCNs bring general practice together with professionals such as clinical pharmacists, physiotherapists, mental-health practitioners and social prescribers. This can improve access without requiring a new private GP clinic. It also means that a start-up should research which services are already available through the relevant neighbourhood pathway.

How neighbourhood commissioning shapes service opportunities

The PNA reflects the NHS direction towards more prevention, digital care and services outside hospitals. Telford & Wrekin's Integrated Place Partnership is intended to support this by linking primary care, community health, public health, local government and voluntary organisations.

For providers, this may create opportunities to support people with long-term conditions, manage medicines, offer preventative care or provide specific diagnostic or rehabilitation services closer to home.

But a strategic objective is not the same as a tender. An organisation planning to sell NHS-funded services should establish the actual commissioner, budget, eligibility criteria, referral arrangements and contracting route before committing to staff or premises.

Some clinics may instead be entirely privately funded. That market requires separate evidence of purchasing power and willingness to pay.

Community pharmacy supply: sufficient overall despite a lower rate per head

As of the November 2025 reference point in the final PNA, Telford & Wrekin had 35 community pharmacies, alongside one dispensing GP and one dispensing appliance contractor.

The PNA calculates 17.9 community pharmacies per 100,000 residents, against 19.5 for England. With the dispensing GP practice included, the corresponding rate is 18.4 per 100,000, versus 21.0 nationally.

1. Telford & Wrekin17.9
2. England19.5

1621

These comparisons could suggest an apparent shortage if read in isolation. However, the PNA considers actual access, opening hours, dispensing services, neighbouring services and the county's compact geography. Its conclusion is that necessary pharmacy provision remains adequate through March 2029.

The assessment does not identify a need that can only be met by approving a new pharmacy. A prospective operator should therefore not use the lower density figure to claim an NHS contractor opportunity.

Other forms of pharmacy improvement may be possible, particularly through clinical services delivered by existing contractors.

Access around Newport and the borough's rural edges

Most community pharmacies are located in the borough's urban centres. The PNA records no community pharmacies in rural-classified areas, but Wellington Road Surgery in Newport provides dispensing to eligible patients.

The geographical picture is favourable for much of the population. Fewer than 30 properties were estimated to be more than a six-mile radius from a community pharmacy in the October 2025 mapping analysis.

Nevertheless, distance and convenience are not the same as equitable access. People without private transport, those with mobility problems, older patients and residents needing accessible communication may face difficulties even when pharmacies are nearby.

The majority of households have access to a car, but not all. A clinic or pharmacy claiming to improve access needs to demonstrate how the affected patient group can actually use the service, including public transport, accessible premises and non-digital contact routes.

Opening hours are uneven between localities

The 2026 PNA lists six pharmacies operating at least 72 hours a week. These provide a wider offer across the principal urban areas.

The West locality has weaker evening and weekend access than central areas. Southern Telford also has more limited Saturday-evening and Sunday opening within its immediate locality, although town-centre providers give alternative access.

The document encourages improvements to weekend and out-of-hours access. This is a service-quality and convenience issue, not an identified statutory requirement for an additional dispensing pharmacy.

A prospective business might consider whether a different opening schedule has commercial merit, but it should also account for staff cost, existing extended-hour rivals and actual patient willingness to travel.

The statutory sufficiency conclusion is a baseline for judging new pharmacy applications, not a claim that every person finds services easy to use. Opening hours and travel patterns vary among the PNA's four localities. A prospective provider should therefore distinguish the absence of a formally identified need for another pharmacy from a possible opportunity to improve the reliability, accessibility or take-up of services already available.

A useful investment test is whether the intended activity requires a new premises, different commissioned hours, clinical outreach or better signposting to current pharmacies. These responses have very different cost structures and regulatory routes, even where the underlying patient problem sounds similar.

Pharmacy First is already part of the local urgent-care market

All 35 community pharmacies had signed up to Pharmacy First in the PNA's review. The service provides NHS-funded consultations for specified common conditions that might otherwise lead to GP or urgent-care visits.

The council and ICB want to increase referrals from GPs and NHS 111 and improve public awareness. These priorities suggest that existing clinical pharmacy provision could be used more effectively.

For a private minor-illness clinic, Pharmacy First is a direct competitor for certain presentations. A patient will not automatically pay privately for a consultation that is available through a convenient NHS-funded channel.

A new service should therefore be clear about the clinical complexity, speed, continuity or specialist treatment that distinguishes it from existing pathways.

Screening is widespread, but follow-up matters

The PNA describes considerable expansion of the pharmacy Hypertension Case-finding Service. Between May 2024 and April 2025, 32 pharmacies carried out blood-pressure checks and completed 11,613 checks. The document records 520 ambulatory blood-pressure monitoring episodes associated with the service.

This indicates existing screening capability across most of the borough. The remaining opportunity is not simply more devices for measuring blood pressure. It is effective targeting, follow-up, referral and management of people at risk of cardiovascular disease.

The PNA recommends closer working between pharmacists, PCNs and local healthy-lifestyles programmes. A new healthcare operator would need to show what additional value its model contributes.

Vaccination coverage is not the same as uptake

The final PNA reports that almost all pharmacies were signed up to deliver NHS flu vaccinations. Nevertheless, uptake among at-risk people was only 38.5% in 2024/25, below the 55% benchmark cited in the document. Uptake among older people was 72.9% and had deteriorated compared with previous seasons.

This is a genuine public-health challenge despite the presence of a substantial provider network.

A suitable response might focus on more flexible vaccination delivery, communications, particular communities or outreach. It would need to establish whether the work was NHS-funded, locally commissioned or purchased privately.

A company that simply opens another vaccination site without considering patient uptake and current local provision may not solve the problem.

The hypertension and vaccination figures illustrate an important commissioning distinction. Screening or vaccination capacity may already exist in numerous pharmacies, but patient outcomes depend on who attends, which groups are missed and how referrals are followed through. More devices and appointments are not necessarily the most effective response to low uptake or incomplete follow-up.

A specialist provider could potentially support targeted outreach or a defined clinical pathway, but should demonstrate why current PCN and pharmacy arrangements cannot deliver it as effectively. An identified public-health priority establishes a problem worth addressing; it does not establish that an NHS contract or private market is available.

Sexual and reproductive health has a strong locality component

Central South has a younger population, with a corresponding need for contraception and sexual-health access.

The PNA records 694 ongoing contraception consultations and 169 initiation consultations through community pharmacies between May 2024 and April 2025. The national Pharmacy Contraception Service has subsequently expanded, including emergency hormonal contraception from October 2025.

The council encourages increased service activity, especially in Central South, and better links with existing sexual-health pathways.

A new women's-health or sexual-health provider should investigate the actual care gap, whether it concerns appointment access, complex care, privacy, continuity or referral, rather than duplicate the basic pharmacy service already available.

Smoking cessation and effective community support

Smoking-related illness and preventable mortality are significant local health issues. The PNA identifies challenges in the uptake and availability of some pharmacy-delivered cessation pathways.

The NHS Smoking Cessation Service serves a defined group of patients, and local partners have discussed extending community-pharmacy involvement in wider stop-smoking provision.

The commissioning route matters here. A provider should determine whether a service is already publicly funded, how patients are referred and what outcome is being purchased. High prevalence of smoking does not automatically establish a viable direct-pay market.

Harm reduction priorities by postcode

The 2026–29 PNA recommends increased provision of needle exchange and naloxone access, particularly in TF1, TF3 and TF7. It also identifies a need for more active supervised-consumption provision in TF1, TF2, TF3, TF4 and TF7, with particular emphasis on TF1 and TF3.

These are specific local service-development priorities. They relate to harm reduction, public-health access and active participation by suitable providers.

They should not be described as a shortage of general community pharmacies. A relevant provider needs the correct training, governance, safeguarding and locally commissioned contract.

Private healthcare and diagnostics: a separate commercial assessment

Telford's population and business base may support private GP appointments, diagnostics, physiotherapy, dermatology, women's health and other outpatient services.

But the commercial case varies considerably by neighbourhood. A service aimed at professional households or commuters will have different fee and access assumptions from one aimed at areas with greater deprivation.

Research should include the actual target patient group, competing providers, NHS alternatives, prices, clinical workforce, likely referral channels and the frequency with which patients would use the service.

A specialist diagnostic service should also establish how results are reported, who provides follow-up and where the patient is referred if further investigation or treatment is required.

The key distinction is between population health need and the existence of someone willing and able to buy a particular service.

Mental health, neurodevelopmental care and employers

The wider local health system faces demand for mental-health and neurodevelopmental services. A private assessment or therapy business should define whether it offers diagnosis, treatment, prescribing, follow-up or care coordination. Each involves different clinical governance and regulatory responsibilities.

Waiting lists may signal demand, but do not by themselves demonstrate NHS procurement opportunities or sustainable private payment.

Telford's employers in manufacturing, logistics, engineering and services may also purchase occupational health, absence management, health surveillance or vaccinations. This is a separate employer-funded market that needs to be assessed through actual contracts and purchasing requirements.

Across these sectors, specialist capability and a clear referral or payment route matter more than claims about general healthcare demand.

The borough's housing growth also creates a timing problem for clinic investors. Future residents may increase the need for GP appointments, prescriptions and allied healthcare, but planned homes and projected population are not today's patient registrations. A premises-led business should model phased occupation and the changing practice catchment, not assume all anticipated residents will become paying customers on opening.

Similarly, private-pay and employer-funded clinics require distinct evidence. A high-prevalence condition in a disadvantaged neighbourhood may justify publicly funded outreach without creating substantial private willingness to pay. Employer contracts depend on actual occupational-health requirements and procurement rather than population figures.

Regulatory scope and NHS market entry are not the same

A private clinic may require CQC registration for regulated activities such as Treatment of disease, disorder or injury or Diagnostic and screening procedures, depending on what it actually delivers.

A pharmacy has separate General Pharmaceutical Council and NHS pharmaceutical-list obligations. Dental providers have their own clinical and contractual requirements.

CQC registration does not guarantee entitlement to NHS-funded activity. Before applying, the organisation should clarify the clinical service model, staff professional registration, premises, patient safety, information governance and commissioning or private-purchase arrangements.

What the local evidence supports

This is a substantial healthcare market, but one where more appropriate use of existing capacity is often the relevant opportunity.

Questions before opening a clinical service

Which PCN or PNA locality will the service cover? What patient group is it intended for? Which NHS or private route already provides similar care? Is the current problem availability, uptake, travel, affordability or a specialist clinical gap?

What will patients or commissioners pay, and how will referrals be obtained? Can the business recruit qualified clinicians, establish safe follow-up and meet premises and regulatory requirements?

For pharmacies, the final PNA and live pharmaceutical list must be used. For private services, the market case needs to be tested independently of NHS strategic statements.